# ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

Source: https://onco.cc/trials/nct05446298/  
OnCo record `nct05446298` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Gotistobart, Pembrolizumab in ovarian cancer, run by OncoC4, Inc., active and no longer recruiting.

## Summary

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer is a phase 2 interventional study registered as NCT05446298 by OncoC4, Inc., with 58 participants enrolled, started 2022-12-22 and due to reach its primary completion in 2026-08-30. Interventions recorded: ONC-392, Pembrolizumab. Conditions listed: Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05446298
- Phase: 2
- Setting: Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients With Platinum Resistant Ovarian Cancer (PROC)
- Sponsor: OncoC4, Inc.
- Enrolled: 58

## Sources

- ClinicalTrials.gov NCT05446298: https://clinicaltrials.gov/study/NCT05446298

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Gotistobart](https://onco.cc/drugs/gotistobart/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [OncoC4](https://onco.cc/companies/oncoc4/)

---
JSON: https://onco.cc/api/v1/entities/nct05446298.json